U.S. Oil and Gas Stock News

GE HealthCare Technologies (GEHC) has put its Photonova Spectra photon-counting CT system in the spotlight after securing U.S. FDA 510(k) clearance, a regulatory milestone that validates commercial use for advanced cardiac imaging. See our latest analysis for GE HealthCare Technologies. The FDA 510(k) clearance for Photonova Spectra arrives after a period in which GE HealthCare’s 1 month share price return of 10.2% and year to date share price return of 13.09% have been weak. At the same...

Teledyne Technologies (NYSE:TDY) has secured a major contract with the UK Ministry of Defence to supply autonomous ocean observing systems for the Royal Navy. The company has reorganized its space focused operations into a new initiative called Teledyne Space, combining multiple space related capabilities. These moves highlight Teledyne's focus on advanced maritime and space technologies that are closely tied to defense and national security needs. For investors tracking NYSE:TDY, the new...

Earnings surprise and guidance put focus on Lattice Semiconductor Lattice Semiconductor (LSCC) drew attention after reporting quarterly revenue above expectations, tighter inventories, and data center strength linked to AI, while issuing next quarter revenue guidance that also topped analyst forecasts. See our latest analysis for Lattice Semiconductor. The latest results come after a sharp run in the share price, with a 90 day share price return of 29.85% and a 1 year total shareholder return...

Recent shareholder litigation and board-level fiduciary duty questions have pushed Fiserv (FISV) into focus, as a class action complaint and law firm investigation intersect with cautious analyst ratings and a consensus Hold stance. See our latest analysis for Fiserv. At a share price of US$55.45, Fiserv has a 1 month share price return of 10.35% and a year to date share price return of 15.46%. The 1 year total shareholder return of 75.48% and 5 year total shareholder return of 54.96% point...

In March 2026, the FDA’s Center for Biologics Evaluation and Research issued an untitled letter to Iovance Biotherapeutics over Amtagvi promotional materials, citing potentially misleading references to overall survival data and giving the company 15 working days to respond. This regulatory pushback highlights the sensitivity around how Iovance communicates clinical outcomes for its first commercial product, a key element of its growth ambitions. We’ll now explore how the FDA’s concerns over...

Context for CareTrust REIT after recent price moves CareTrust REIT (CTRE) has seen mixed share performance recently, with a gain of 1.3% over the past day, a small decline over the past week, and a larger drop over the past month. See our latest analysis for CareTrust REIT. That short term weakness sits alongside a 2.3% year to date share price return and a 35.5% total shareholder return over the past year, supported by even stronger 3 and 5 year total shareholder returns. If CareTrust REIT’s...

If you are wondering whether Tripadvisor is a bargain at its current share price or cheap for a reason, this article breaks down what the market might be implying about its value. The stock last closed at US$10.71, with a 12.6% return over the past week and 7.3% over the past month, but a 26.8% decline year to date and a 25.2% decline over the past year. Recent headlines around Tripadvisor have focused on ongoing competition among travel platforms and how consumer behavior is evolving as...

Garmin (NYSE:GRMN) has entered a partnership with Natural Cycles to integrate FDA cleared fertility and reproductive health tracking into compatible Garmin smartwatches. The collaboration brings non hormonal birth control and detailed fertility insights to Garmin's wearable platform through Natural Cycles' approved algorithm. The integration extends Garmin's health tracking capabilities into reproductive health, targeting users seeking data driven support for cycle tracking and family...

In recent months, Deckers Outdoor has earned a Zacks Rank #1 (Strong Buy) after a series of quarterly earnings and revenue beats and upward analyst estimate revisions, reflecting improved expectations for its near‑term performance. At the same time, the company’s constant-currency growth and operating margin have trailed industry benchmarks, highlighting an interesting contrast between analyst optimism and underlying profitability pressures. We’ll now examine how this stronger analyst...

On March 17, 2026, at the NVIDIA AI Conference & Expo, Nvidia announced a collaboration with Coupang to build an AI factory that combines Coupang Intelligent Cloud with Nvidia DGX SuperPOD, creating a self-service environment for developing and testing AI models across its global e-commerce, logistics, and delivery operations. This effort positions Coupang as a launch partner for Nvidia Dynamo and signals a deeper integration of advanced AI into its Rocket Delivery and fulfillment network,...

In recent weeks, Celsius Holdings reported quarterly revenue of US$721.63 million and earnings per share of US$0.26, both beating analyst estimates, while Deutsche Bank upgraded its rating after reassessing competition from Costco’s private-label energy drink and the company’s integration of Alani Nu and Rockstar. Together with Celsius’s roughly 20% share of U.S. energy drink dollars and expectations for gross margin recovery to the low 50s by mid-2026, these developments highlight how brand...

Why Kodiak Gas Services is on investors’ radar Kodiak Gas Services (KGS) has drawn attention after a strong past 3 months, with the stock showing a 54.8% total return while operating a US focused contract compression and services business. See our latest analysis for Kodiak Gas Services. That recent 54.8% 3 month share price return contrasts with a softer 7 day share price return of a 2.1% decline. The latest close at $57.90 sits against a 1 year total shareholder return of 57.3%, suggesting...

Eli Lilly (NYSE:LLY) received U.S. FDA approval for Foundayo, its first oral, once-daily GLP-1 weight loss pill for obesity and overweight patients with related conditions. The company launched Foundayo commercially in the U.S. immediately after approval, making it available through LillyDirect and retail pharmacies. Foundayo can be taken at any time without food or water restrictions and is being introduced with tailored pricing to broaden access. Eli Lilly enters a new phase in obesity...

In late March 2026, Moderna participated in the World Vaccine Congress Washington and the 4th annual Entrepreneurship Summit, where senior leaders highlighted its evolving mRNA vaccine and cancer-therapy ambitions while the company continued to address operational and legal challenges. Together with a multi‑billion‑dollar patent settlement and progress toward individualized cancer vaccines, these events underline Moderna’s attempt to reset its long‑term direction beyond COVID‑19. Next,...

Snap (SNAP) is back in the spotlight after activist investors Irenic Capital Management and Randian Capital publicly pressed for sweeping changes, including a potential Spectacles spin off, tighter costs, and a sharper focus on artificial intelligence. See our latest analysis for Snap. The recent activist letters arrived after a long stretch of weak performance, with the share price at US$4.90 and a year-to-date share price return of about 40% in decline. The 1-year total shareholder return...

C.H. Robinson Worldwide (CHRW) has responded to higher diesel costs tied to a new Middle East conflict by rolling out free discount fuel cards and temporary fee free cash advances for its contract carriers. See our latest analysis for C.H. Robinson Worldwide. The latest diesel support measures arrive at a time when C.H. Robinson’s share price has been volatile, with a 1-day share price return of 1.46%, a 30-day share price return of 10.01%, and a 1-year total shareholder return of 66.99%...

If you are wondering whether Varonis Systems at around US$21.74 is starting to look interesting on price, the key question is how that tag compares with what the business might reasonably be worth. The stock has seen mixed returns, with a 1.6% move over the last 7 days, a 5.8% decline over 30 days, and much steeper negative returns of 32.1% year to date and 47.7% over the past year. These moves have kept Varonis on many watchlists as investors reassess their appetite for higher risk software...

Paramount Skydance (NasdaqGS:PSKY) has won a high profile bidding war to acquire Warner Bros. Discovery in a historic media merger. The deal creates one of the largest combined film, TV, and streaming groups, but leaves the company with a substantially elevated post deal debt load. Industry commentary is widely critical of the high leverage, with some questioning whether the transaction could threaten Paramount Skydance’s future viability. The acquisition is subject to an extended Department...

Company overview and recent stock performance Nektar Therapeutics (NKTR) has drawn fresh attention after an extended run in its share price, with the stock showing strong returns over the past 3 months and the past year. For context, Nektar is a US based biopharmaceutical company focused on immunotherapy, with a pipeline that includes rezpegaldesleukin in Phase 2b for autoimmune and inflammatory diseases, plus several earlier stage candidates targeting autoimmune and fibrotic conditions, as...

Peridio recently announced it has joined the NXP Semiconductors Partner Program as a Registered Partner, deepening their collaboration around Avocado OS and NXP’s i.MX processors and Ara discrete neural processing units for edge AI devices. This move highlights how NXP’s edge AI hardware is increasingly being paired with production-grade software infrastructure, positioning its platforms as a turnkey option for manufacturers facing tighter cybersecurity and regulatory requirements. We’ll now...

In late March 2026, Phreesia, Inc. reported fourth-quarter and full-year results showing higher revenue and a swing to GAAP profitability, while also cutting its fiscal 2027 revenue outlook to US$510 million–US$520 million amid reduced visibility into pharmaceutical client spending. The company simultaneously filed a US$34.61 million shelf registration for 3,033,251 common shares tied to an ESOP-related offering, highlighting ongoing use of equity-based compensation even as management guides...

In late March 2026, Disneyland Paris opened its World of Frozen expansion and reintroduced its second gate as Disney Adventure World, a multibillion‑dollar immersive upgrade anchored by new attractions, a central lake, and a nighttime spectacular. This expansion, alongside Disney’s broader parks and streaming push, highlights how the company is leaning on experiential IP to reinforce its position as a global tourism and media powerhouse. With Disney’s largest‑ever Disneyland Paris expansion...

Janux Therapeutics has nominated a tumor activated cancer therapeutic using its TRACTr platform in partnership with Bristol Myers Squibb, triggering a $35 million milestone payment. Bristol Myers Squibb is expanding its "Standing in the Gaap" multiple myeloma care survey, aiming to better understand and address equity gaps in treatment. NYSE:BMY is adding fresh R&D momentum through its collaboration with Janux, as the new tumor activated candidate moves closer to potential clinical...

RLI Corp. recently promoted Cory Figiel to Chief Claim Officer and elevated Charles Spiekerman to Vice President, Claim, while its Transportation division partnered with Transportation Advisors to offer policyholders discounted, AI-enabled compliance and safety services for commercial fleets. These leadership moves and the transportation compliance partnership come shortly after RLI reported a quarter where earnings outpaced expectations but book value per share lagged analyst estimates,...